fascaplysine has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Funovics, M; Hamilton, G; Hochmair, M; Neumayer, C; Plangger, A; Rath, B; Zeillinger, R | 1 |
| Luo, L; Xu, G | 1 |
| Hamilton, G; Hochmair, M; Plangger, A; Rath, B | 1 |
3 other study(ies) available for fascaplysine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin-Dependent Kinase 4; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression.
Topics: Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Ferroptosis; Immunologic Factors; Immunotherapy; Lung Neoplasms; Mice; Reactive Oxygen Species | 2022 |
Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Humans; Indoles; Lung Neoplasms; Neoplastic Cells, Circulating; Signal Transduction | 2018 |